Nothing Special   »   [go: up one dir, main page]

CR7716A - Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor - Google Patents

Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor

Info

Publication number
CR7716A
CR7716A CR7716A CR7716A CR7716A CR 7716 A CR7716 A CR 7716A CR 7716 A CR7716 A CR 7716A CR 7716 A CR7716 A CR 7716A CR 7716 A CR7716 A CR 7716A
Authority
CR
Costa Rica
Prior art keywords
ikb
kinase inhibitors
pain treatment
inhibitors
pain
Prior art date
Application number
CR7716A
Other languages
English (en)
Inventor
Michaelis Martin
Ritzeler Olaf
Jaehne Gerhard
Rudolphi Karl
Geisslinger Gerd
Schaible Hans-Georg
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR7716A publication Critical patent/CR7716A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invencion se refiere al uso de inhibidores de la IkB-quinasa que son adecuados para la preparacion de medicamentos para tratar dolores. Los inhibidores adecuados son compuestos de las formulas (i) y (Ia).
CR7716A 2002-08-17 2005-03-07 Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor CR7716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Publications (1)

Publication Number Publication Date
CR7716A true CR7716A (es) 2008-11-25

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7716A CR7716A (es) 2002-08-17 2005-03-07 Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor

Country Status (34)

Country Link
EP (1) EP1531819B1 (es)
JP (1) JP4504811B2 (es)
KR (2) KR101119845B1 (es)
CN (1) CN100398107C (es)
AR (1) AR043045A1 (es)
AT (1) ATE418336T1 (es)
AU (1) AU2003271555B2 (es)
BR (1) BR0313555A (es)
CA (1) CA2495455C (es)
CO (1) CO5690585A2 (es)
CR (1) CR7716A (es)
CY (1) CY1108874T1 (es)
DE (2) DE10237723A1 (es)
DK (1) DK1531819T3 (es)
EC (1) ECSP055609A (es)
ES (1) ES2320118T3 (es)
HK (1) HK1079426A1 (es)
HR (1) HRP20050041B1 (es)
IL (1) IL166780A (es)
MA (1) MA27334A1 (es)
MX (1) MXPA05001218A (es)
MY (1) MY138059A (es)
NO (1) NO334309B1 (es)
OA (1) OA12907A (es)
PL (1) PL212356B1 (es)
PT (1) PT1531819E (es)
RS (1) RS51878B (es)
RU (1) RU2320338C2 (es)
SI (1) SI1531819T1 (es)
TN (1) TNSN05044A1 (es)
TW (1) TWI325782B (es)
UA (1) UA80837C2 (es)
WO (1) WO2004022057A1 (es)
ZA (1) ZA200500323B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
CA2578636A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5790440B2 (ja) * 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20140103968A (ko) * 2011-12-06 2014-08-27 사노피 2-(2-메틸아미노-피리미딘-4-일)-1h-인돌-5-카복실산 [(s)-1-카바모일-2-(페닐-피리미딘-2일-아미노)-에틸]-아미드의 결정 형태
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CA2951972A1 (en) * 2014-07-03 2016-01-07 Sanofi 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis
JP2021530505A (ja) 2018-07-16 2021-11-11 ノバルティス アーゲー フェニルピペリジニルインドール誘導体を調製する化学的プロセス

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261248C2 (ru) * 1999-06-23 2005-09-27 Авентис Фарма Дойчланд Гмбх Замещенные бензимидазолы и лекарственное средство на их основе
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
RU2005107419A (ru) 2005-08-10
JP4504811B2 (ja) 2010-07-14
BR0313555A (pt) 2005-07-12
MXPA05001218A (es) 2005-05-16
AR043045A1 (es) 2005-07-13
HK1079426A1 (en) 2006-04-07
TW200417370A (en) 2004-09-16
ATE418336T1 (de) 2009-01-15
NO334309B1 (no) 2014-02-03
JP2005539053A (ja) 2005-12-22
PL212356B1 (pl) 2012-09-28
DE10237723A1 (de) 2004-07-08
WO2004022057A1 (de) 2004-03-18
OA12907A (en) 2006-10-13
SI1531819T1 (sl) 2009-06-30
CA2495455C (en) 2011-01-11
PT1531819E (pt) 2009-02-18
ZA200500323B (en) 2006-02-22
HRP20050041B1 (hr) 2013-07-31
TWI325782B (en) 2010-06-11
CO5690585A2 (es) 2006-10-31
KR101119845B1 (ko) 2012-02-28
AU2003271555B2 (en) 2009-03-26
HRP20050041A2 (hr) 2006-04-30
TNSN05044A1 (en) 2007-05-14
RS20050070A (en) 2007-06-04
CN1674899A (zh) 2005-09-28
NO20051339L (no) 2005-05-03
DE50310980D1 (de) 2009-02-05
RS51878B (sr) 2012-02-29
MA27334A1 (fr) 2005-05-02
ES2320118T3 (es) 2009-05-19
KR20050058339A (ko) 2005-06-16
IL166780A0 (en) 2006-01-15
MY138059A (en) 2009-04-30
ECSP055609A (es) 2005-04-18
IL166780A (en) 2011-11-30
PL373568A1 (en) 2005-09-05
AU2003271555A1 (en) 2004-03-29
CA2495455A1 (en) 2004-03-18
KR20110135428A (ko) 2011-12-16
EP1531819A1 (de) 2005-05-25
CY1108874T1 (el) 2014-07-02
EP1531819B1 (de) 2008-12-24
CN100398107C (zh) 2008-07-02
RU2320338C2 (ru) 2008-03-27
DK1531819T3 (da) 2009-04-20
UA80837C2 (uk) 2007-11-12

Similar Documents

Publication Publication Date Title
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
SV2003000925A (es) Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
UY28342A1 (es) Nuevos compuestos
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
UY28572A1 (es) Compuestos novedosos
HN2008000949A (es) Derivados de pirimidinil- aril- urea que son inhibidores de fgf
UY27740A1 (es) Nuevos compuestos
AR028948A1 (es) Compuestos novedosos
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
PA8514901A1 (es) Metabolitos agonistas/antagonistas de estrogeno
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.